The Effect of Laser Thermal Ablation on Quality of Life: Improvements in Patients with Solid-Cystic Thyroid Nodules

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

The Effect of Laser Thermal Ablation on Quality of Life : Improvements in Patients with Solid-Cystic Thyroid Nodules. / Sorensen, Jesper Roed; Døssing, Helle; Watt, Torquil; Cramon, Per; Hegedüs, Laszlo; Bonnema, Steen Joop; Folkestad, Lars.

In: Thyroid, Vol. 32, No. 8, 2022, p. 917-925.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Sorensen, JR, Døssing, H, Watt, T, Cramon, P, Hegedüs, L, Bonnema, SJ & Folkestad, L 2022, 'The Effect of Laser Thermal Ablation on Quality of Life: Improvements in Patients with Solid-Cystic Thyroid Nodules', Thyroid, vol. 32, no. 8, pp. 917-925. https://doi.org/10.1089/thy.2021.0665

APA

Sorensen, J. R., Døssing, H., Watt, T., Cramon, P., Hegedüs, L., Bonnema, S. J., & Folkestad, L. (2022). The Effect of Laser Thermal Ablation on Quality of Life: Improvements in Patients with Solid-Cystic Thyroid Nodules. Thyroid, 32(8), 917-925. https://doi.org/10.1089/thy.2021.0665

Vancouver

Sorensen JR, Døssing H, Watt T, Cramon P, Hegedüs L, Bonnema SJ et al. The Effect of Laser Thermal Ablation on Quality of Life: Improvements in Patients with Solid-Cystic Thyroid Nodules. Thyroid. 2022;32(8):917-925. https://doi.org/10.1089/thy.2021.0665

Author

Sorensen, Jesper Roed ; Døssing, Helle ; Watt, Torquil ; Cramon, Per ; Hegedüs, Laszlo ; Bonnema, Steen Joop ; Folkestad, Lars. / The Effect of Laser Thermal Ablation on Quality of Life : Improvements in Patients with Solid-Cystic Thyroid Nodules. In: Thyroid. 2022 ; Vol. 32, No. 8. pp. 917-925.

Bibtex

@article{f684a8033e434e2b9480b8b14fb40c07,
title = "The Effect of Laser Thermal Ablation on Quality of Life: Improvements in Patients with Solid-Cystic Thyroid Nodules",
abstract = "Background: Evidence of the efficacy of laser thermal ablation (LTA) in benign thyroid nodules is abundant. However, little is known about the effect on quality of life (QoL) of this treatment. Methods: Prospective cohort study investigating the effect of LTA before, three, and six months after LTA on QoL using the thyroid-specific patient-reported outcome (ThyPRO) measure. Patients receiving LTA (laser group [LG]) was compared with a well-characterized control group (CG) from the Danish civil registry. Results: The LG comprised 54 patients, with no age or sex differences compared with the CG (n = 739). Sixty-nine percent of the patients had a recurrent cystic thyroid nodule, 6% had a solid nodule, while the remaining 25% were of mixed character. The median nodule volume was 6.8 mL (interquartile range [IQR]: 4.0-11.1) before LTA, and 1.8 mL (IQR: 0.6-4.1) at 6 months post-LTA (p < 0.001), corresponding to a median reduction of 78%. All cystic fluid (median: 6 mL; IQR: 2.0-9.0) was aspirated before LTA. Median treatment time was 400 seconds (IQR: 300-600), applying a median energy of 823 J (IQR: 600-1200). At baseline and according to the ThyPRO scales, the LG differed significantly from the CG by having more goiter symptoms, hyperthyroid symptoms, tiredness, and cognitive complaints (p < 0.05 for all variables), but only the difference in the goiter symptom scale was of a clinically important magnitude. At three months, the LG experienced a large improvement in goiter symptoms (effect size [ES] = 1.05), a moderate improvement in cosmetic complaints (ES = 0.50), and a moderate improvement in the overall QoL (ES = 0.64). Only the improvements in the goiter symptom and the cosmetic complaint scales were clinically important. Six months after LTA, the anxiety scale showed further improvement of moderate size (ES = 0.52). At 6 months, the results above were maintained, and 79% of patients experienced a large and clinically important improvement in the goiter symptom scale and no clinically important differences were found between the LG and the CG. Conclusions: In this unblinded, prospective observational study, measures of disease-specific QoL were significantly improved compared with preprocedure levels, in patients with solid-cystic nodules.",
keywords = "goiter, laser thermal ablation, quality of life, ThyPRO, thyroid nodule",
author = "Sorensen, {Jesper Roed} and Helle D{\o}ssing and Torquil Watt and Per Cramon and Laszlo Heged{\"u}s and Bonnema, {Steen Joop} and Lars Folkestad",
note = "Publisher Copyright: {\textcopyright} Copyright 2022, Mary Ann Liebert, Inc., publishers 2022.",
year = "2022",
doi = "10.1089/thy.2021.0665",
language = "English",
volume = "32",
pages = "917--925",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary AnnLiebert, Inc. Publishers",
number = "8",

}

RIS

TY - JOUR

T1 - The Effect of Laser Thermal Ablation on Quality of Life

T2 - Improvements in Patients with Solid-Cystic Thyroid Nodules

AU - Sorensen, Jesper Roed

AU - Døssing, Helle

AU - Watt, Torquil

AU - Cramon, Per

AU - Hegedüs, Laszlo

AU - Bonnema, Steen Joop

AU - Folkestad, Lars

N1 - Publisher Copyright: © Copyright 2022, Mary Ann Liebert, Inc., publishers 2022.

PY - 2022

Y1 - 2022

N2 - Background: Evidence of the efficacy of laser thermal ablation (LTA) in benign thyroid nodules is abundant. However, little is known about the effect on quality of life (QoL) of this treatment. Methods: Prospective cohort study investigating the effect of LTA before, three, and six months after LTA on QoL using the thyroid-specific patient-reported outcome (ThyPRO) measure. Patients receiving LTA (laser group [LG]) was compared with a well-characterized control group (CG) from the Danish civil registry. Results: The LG comprised 54 patients, with no age or sex differences compared with the CG (n = 739). Sixty-nine percent of the patients had a recurrent cystic thyroid nodule, 6% had a solid nodule, while the remaining 25% were of mixed character. The median nodule volume was 6.8 mL (interquartile range [IQR]: 4.0-11.1) before LTA, and 1.8 mL (IQR: 0.6-4.1) at 6 months post-LTA (p < 0.001), corresponding to a median reduction of 78%. All cystic fluid (median: 6 mL; IQR: 2.0-9.0) was aspirated before LTA. Median treatment time was 400 seconds (IQR: 300-600), applying a median energy of 823 J (IQR: 600-1200). At baseline and according to the ThyPRO scales, the LG differed significantly from the CG by having more goiter symptoms, hyperthyroid symptoms, tiredness, and cognitive complaints (p < 0.05 for all variables), but only the difference in the goiter symptom scale was of a clinically important magnitude. At three months, the LG experienced a large improvement in goiter symptoms (effect size [ES] = 1.05), a moderate improvement in cosmetic complaints (ES = 0.50), and a moderate improvement in the overall QoL (ES = 0.64). Only the improvements in the goiter symptom and the cosmetic complaint scales were clinically important. Six months after LTA, the anxiety scale showed further improvement of moderate size (ES = 0.52). At 6 months, the results above were maintained, and 79% of patients experienced a large and clinically important improvement in the goiter symptom scale and no clinically important differences were found between the LG and the CG. Conclusions: In this unblinded, prospective observational study, measures of disease-specific QoL were significantly improved compared with preprocedure levels, in patients with solid-cystic nodules.

AB - Background: Evidence of the efficacy of laser thermal ablation (LTA) in benign thyroid nodules is abundant. However, little is known about the effect on quality of life (QoL) of this treatment. Methods: Prospective cohort study investigating the effect of LTA before, three, and six months after LTA on QoL using the thyroid-specific patient-reported outcome (ThyPRO) measure. Patients receiving LTA (laser group [LG]) was compared with a well-characterized control group (CG) from the Danish civil registry. Results: The LG comprised 54 patients, with no age or sex differences compared with the CG (n = 739). Sixty-nine percent of the patients had a recurrent cystic thyroid nodule, 6% had a solid nodule, while the remaining 25% were of mixed character. The median nodule volume was 6.8 mL (interquartile range [IQR]: 4.0-11.1) before LTA, and 1.8 mL (IQR: 0.6-4.1) at 6 months post-LTA (p < 0.001), corresponding to a median reduction of 78%. All cystic fluid (median: 6 mL; IQR: 2.0-9.0) was aspirated before LTA. Median treatment time was 400 seconds (IQR: 300-600), applying a median energy of 823 J (IQR: 600-1200). At baseline and according to the ThyPRO scales, the LG differed significantly from the CG by having more goiter symptoms, hyperthyroid symptoms, tiredness, and cognitive complaints (p < 0.05 for all variables), but only the difference in the goiter symptom scale was of a clinically important magnitude. At three months, the LG experienced a large improvement in goiter symptoms (effect size [ES] = 1.05), a moderate improvement in cosmetic complaints (ES = 0.50), and a moderate improvement in the overall QoL (ES = 0.64). Only the improvements in the goiter symptom and the cosmetic complaint scales were clinically important. Six months after LTA, the anxiety scale showed further improvement of moderate size (ES = 0.52). At 6 months, the results above were maintained, and 79% of patients experienced a large and clinically important improvement in the goiter symptom scale and no clinically important differences were found between the LG and the CG. Conclusions: In this unblinded, prospective observational study, measures of disease-specific QoL were significantly improved compared with preprocedure levels, in patients with solid-cystic nodules.

KW - goiter

KW - laser thermal ablation

KW - quality of life

KW - ThyPRO

KW - thyroid nodule

U2 - 10.1089/thy.2021.0665

DO - 10.1089/thy.2021.0665

M3 - Journal article

C2 - 35570722

AN - SCOPUS:85136339887

VL - 32

SP - 917

EP - 925

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 8

ER -

ID: 321877124